These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27600590)

  • 1. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment?
    Cozzarini C
    Eur Urol; 2017 Jan; 71(1):44-45. PubMed ID: 27600590
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44-5: Preclinical Combinatorial Approach to Enhance Radiotherapy Effects and Reduce its Morbidity May Be Tested in the Clinic.
    Vale S
    Eur Urol; 2017 Aug; 72(2):e32-e33. PubMed ID: 28214030
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Salvador Vale's Letter to the Editor re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44-5. Preclinical Combinatory Approach to Enhance Radiotherapy Effects and Reduce its Morbidity may be Tested in the Clinic: Wider Whole-pelvis Radiotherapy Fields and Enhanced Antitumoral Effect Mediated by T Lymphocytes: A Legitimate Hypothesis?
    Cozzarini C; Benigni F; Fiorino C; Mondino A; Di Muzio N
    Eur Urol; 2017 Aug; 72(2):e34-e35. PubMed ID: 28214033
    [No Abstract]   [Full Text] [Related]  

  • 4. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer.
    Chera BS; Vargas C; Morris CG; Louis D; Flampouri S; Yeung D; Duvvuri S; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):994-1002. PubMed ID: 19619961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the "Hostile Pelvis" for Intensity Modulated Radiation Therapy: The Impact of Anatomic Variations in Pelvic Dimensions on Dose Delivered to Target Volumes and Organs at Risk in Patients With High-Risk Prostate Cancer Treated With Whole Pelvic Radiation Therapy.
    Yirmibeşoğlu Erkal E; Karabey S; Karabey A; Hayran M; Erkal HŞ
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):894-903. PubMed ID: 26104941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity of tomotherapy-based simultaneous integrated boost in whole-pelvis radiation for prostate cancer.
    You SH; Lee JY; Lee CG
    Yonsei Med J; 2015 Mar; 56(2):510-8. PubMed ID: 25684003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions.
    Morikawa LK; Roach M
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):6-16. PubMed ID: 21481721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base.
    Amini A; Jones BL; Yeh N; Rusthoven CG; Armstrong H; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1052-63. PubMed ID: 26581142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole Pelvis Versus Prostate-Only Radiotherapy With or Without Short-Course Androgen Deprivation Therapy and Mortality Risk.
    Braunstein LZ; Chen MH; Dosoretz DE; Salenius SA; Katin MJ; Nanda A; D'Amico AV
    Clin Genitourin Cancer; 2015 Dec; 13(6):555-61. PubMed ID: 26003267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
    Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
    Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radiotherapy in the treatment of cancer of the prostate].
    Dubois JB
    Bull Cancer; 1985; 72(6):549-58. PubMed ID: 3937559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy.
    Pasquier D; Cavillon F; Lacornerie T; Touzeau C; Tresch E; Lartigau E
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):549-54. PubMed ID: 22677369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Radiotherapy of prostatic cancer: staging and radiotherapy planning with transrectal ultrasound].
    Braun J; Hofmann R; Czempiel H
    Urol Int; 1985; 40(1):25-9. PubMed ID: 3883614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does image-guided radiotherapy (IG-IMRT) improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT: In regard to Chung et al. (Int J Radiat Oncol Biol Phys 2008. In press).
    Jothybasu KS; Bahl A; Subramani V; Sharma DN; Rath GK
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1273; author reply 1273. PubMed ID: 18954726
    [No Abstract]   [Full Text] [Related]  

  • 17. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
    Habl G; Katayama S; Uhl M; Kessel KA; Edler L; Debus J; Herfarth K; Sterzing F
    BMC Cancer; 2015 Nov; 15():868. PubMed ID: 26547188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact.
    Garibaldi E; Gabriele D; Maggio A; Delmastro E; Garibaldi M; Bresciani S; Ortega C; Stasi M; Gabriele P
    Panminerva Med; 2016 Jun; 58(2):121-9. PubMed ID: 26785374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy.
    Vargas CE; Demanes J; Boike TP; Barnaba MC; Skoolisariyaporn P; Schour L; Gustafson GS; Gonzalez J; Martinez AA
    Am J Clin Oncol; 2006 Oct; 29(5):451-7. PubMed ID: 17023778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.